We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

On Wednesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $110.42 which represents a decrease of $-1.11 or -1.00% from the prior close of $111.53. The stock opened at $111 and touched ...

On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...